[Federal Register Volume 67, Number 147 (Wednesday, July 31, 2002)]
[Notices]
[Page 49705]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 02-19268]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Child Health and Human Development; Notice 
of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 
U.S.C., as amended. The contract proposals and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the contract proposals, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.


    Name of Committee: National Institute of Child Health and Human 
Development Special Emphasis Panel, To Study the Safety, 
Immunogenicity and Dosage of VI-rEPA Congufate Vaccine.
    Date: September 6, 2002.
    Time: 12 p.m. to 1:30 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: 6100 Executive Blvd 5th Floor, Rockville, MD 20852, 
(Telephone Conference Call).
    Contact Person: Hameed Khan, PhD, Scientific Review 
Administrator, Division of Scientific Review, National Institute of 
Child Health and Human Development, National Institutes of Health, 
6100 Executive Blvd., Room 5E01, Bethesda, MD 20892, 
(301) 496-1485.

(Catalogue of Federal Domestic Assistance Program Nos. 93.209, 
Contraception and Infertility Loan Repayment Program; 93.864, 
Population Research; 93.865, Research for Mothers and Children; 
93.929, Center for Medical Rehabilitation Research, National 
Institutes of Health, HHS)


    Dated: July 24, 2002.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 02-19268 Filed 7-30-02; 8:45 am]
BILLING CODE 4140-01-M